重组人促红细胞生成素防治早产儿贫血的疗效观察

Clinical observation on the effect of recombinant erythropoietin in the prevention and treatment of anemia of premature

目的:探讨重组人促红细胞生成素(rHu-Epo)防治早产儿贫血的疗效。方法:将60例早产儿随机分为治疗组和对照组各30例,治疗组出生第三天即rHu-Epo250IU/(kg·d),隔日1次,每周3次皮下注射,共6周;对照组未用rHu-Epo。两组早产儿自出生第三天起口服铁剂[元素铁5mg/(kg·d)]。结果:治疗组网织红细胞及血红蛋白明显高于对照组(P<0.01);治疗组输血率与对照组比较明显减少;治疗组体重增长速率明显高于对照组。结论:早期应用大剂量rHu-Epo能有效地防治早产儿贫血,减少输血,体重增长快,且用药安全,无明显不良反应。

Objective：To study the effect of recombinant erythropoietin in the prevention and treatment of anemia of premature. Methods：60 prematures were randomly divided into two groups：treatment group（30 prematures） and control group （30 prematures）,rHu- Epo 750 IU/（kg.w）was given to the treatment group three times a week,one time every 2 days for 6 weeks from the third day of life. Both of these two groups had oral supplement of elemental iron 5 mg/（kg.d） from the third day of life.Results：The initial fall in the reticulocyte count in treatment group had a marked increase compared with the control group （P〈0.01）.The Hb of treatment group had a marked increase compared with the control group. The need for transfusion in the treatment group was significantly less than that in the control group. There were statistically significant differences between the two groups in the rate of weight in crease.Conclusion：Early administration of high dosage of rHu-Epo can hghten the degree of anemia ,reduce or replace the need for blood transfusion, rHu-Epo is efficacious and safe for the treatment of anemia of premature.